Expand all sections

Pembrolizumab

Keytruda

Extended indication Adjuvant melanoma stage III - post-resection adjuvant therapy in high-risk patients.
Therapeutic value No judgement
Total cost 21,350,000.00

Product

Active substance Pembrolizumab
Domain Oncology and Hematology
Main indication Skin cancer
Extended indication Adjuvant melanoma stage III - post-resection adjuvant therapy in high-risk patients.
Proprietary name Keytruda
Manufacturer MSD
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Expected Registration 2018
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding.

Therapeutic value

Current treatment options Alle PD1 en PDL1 remmers worden verwacht voor deze indicatie
Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

< 427

Market share is generally not included unless otherwise stated.
References NKR; Oncoline
Additional remarks NKR 2015: 427 diagnoses melanoom stadium 3. Oncoline: momenteel wordt er niet geadviseerd om patiënten met melanoom buiten onderzoeksverband systemisch adjuvante behandeling te geven.

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl
Additional remarks €3.355,96 per injectieflacon van 4 ml, 25 mg/ml.

Potential total cost per year

Total cost

21,350,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.